Amicus Therapeutics (FOLD) – Major News
-
Amicus Therapeutics (FOLD) Tops Q4 EPS by 7c, provides guidance
-
Amicus Therapeutics (FOLD) Tops Q3 EPS by 1c
-
Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c
-
Amicus Therapeutics (FOLD) Misses Q1 EPS by 4c
-
Amicus Therapeutics (FOLD) Reports In-Line Q2 EPS
-
Amicus Therapeutics (FOLD) Tops Q3 EPS by 8c, Revenues Miss; Raises FY19 Galafold Revenue Guidance
-
Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
-
Amicus Therapeutics (FOLD) Misses Q1 EPS by 25c
-
Amicus Therapeutics (FOLD) Misses Q3 EPS by 56c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
-
Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c
-
Amicus Therapeutics (FOLD) Phase 3 Results for SD-101 Fails to Meet Primary or Secondary Endpoints
-
Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34
-
Amicus Therapeutics (FOLD) Misses Q1 EPS by 3c
-
Amicus Therapeutics (FOLD) Tops Q3 EPS by 1c; Affirms FY16 Net Cash Spend Outlook
-
Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
-
UPDATE: Amicus Therapeutics' (FOLD) Galafold Wins EMA Backing for Approval to Treat Fabry Disease
-
Amicus Therapeutics (FOLD) Unlikley to Submit NDA for Migalastat Monotherapy This Year
-
Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
-
Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c
-
Amicus Therapeutics (FOLD) Misses Q4 EPS by 6c
-
Amicus Therapeutics (FOLD) Reports Positive Phase 3 Data From Fabry Monotherapy Study 012
-
Amicus Therapeutics, Inc. (FOLD) Tops Q4 EPS by 10c
-
Amicus Therapeutics (FOLD) Acquires Callidus Biopharma; Issues Strategic Update
-
Amicus (FOLD), Glaxo (GSK) Amend Fabry ERT Agreement
-
Amicus Therapeutics, Inc. (FOLD) Posts Q3 Loss of $0.34/Sh
-
Amicus Therapeutics, Inc. (FOLD) Posts Q2 Loss of 31c/Share
-
Amicus Therapeutics, Inc. (FOLD) Posts Q4 Loss of 20c/Share
-
Amicus (FOLD) Sees Net Cash Spend Up to $58M in FY13; Provides Update
-
Amicus Therapeutics, Inc. (FOLD) Misses Q3 EPS by 7c
-
Amicus Therapeutics, Inc. (FOLD) Tops Q1 EPS by 1c; Guides In-line
-
Amicus Therapeutics, Inc. (FOLD) Tops Q4 EPS by 12c
-
Amicus Therapeutics, Inc. (FOLD) Tops Q3 EPS by 5c
-
Amicus Therapeutics, Inc. (FOLD) Reports Q1 EPS Loss of $0.39
-
Amicus Therapeutics, Inc. (FOLD) Misses Q4 Views
-
Amicus Therapeutics (FOLD) Posts Stronger Q2 Results; Updates on Product Pipeline
-
Amicus Therapeutics, Inc. (FOLD) Swings to Q4 EPS of $1.45, Beats Views
-
Amicus Therapeutics (FOLD) Reports Better-Than-Expected Q2 Adj-Loss of $0.51
-
Amicus Therapeutics (FOLD) Reports Smaller Than Expected Q1 Loss; Revs Light
-
Amicus Therapeutics (FOLD) Tops Q4 EPS by 7c, Comments on FY09
-
Amicus Therapeutics (FOLD) Reports a Narrower Q3 Loss; Comments on FY08
-
Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.33
-
Amicus Therapeutics (FOLD) Tops Q1 EPS by 10c
Back to FOLD Stock Lookup